美国多发性骨髓瘤新型疗法引入后的死亡率趋势
该研究对比2004至2018年Mayo Clinic的3783例患者与SEER项目的57654例患者,发现两个人群的早期死亡率均下降、估计5年总生存率均提高,但超额死亡率在Mayo Clinic患者中随时间下降而在SEER患者中基本不变。
要点
- 两个人群的早期死亡率均下降且估计5年总生存率均提高。
- 超额死亡率在Mayo Clinic患者中下降,在SEER患者中基本不变。
- 老年及不良疾病特征患者仍为脆弱人群,获益相对不足。
核心结论
- 不同患者人群及亚组的死亡率趋势存在差异,社区患者超额死亡率未见改善。
研究设计与样本
- 对比2004至2018年Mayo Clinic的3783例患者与SEER项目的57654例患者的总生存经验。
主要发现
- 两个人群的早期死亡率均随时间下降且估计5年总生存率均提高。
- 超额死亡率在Mayo Clinic患者中随时间下降,在SEER患者中基本不变。
- 改善主要见于具有有利疾病特征的患者。
- 老年多发性骨髓瘤患者仍为脆弱人群,相较美国一般人群存在显著超额死亡率。
- 具有不利疾病特征的患者从近期进展中获得的获益不成比例地较少。
临床怎么用
- 未来需聚焦为不利疾病特征患者开发安全有效的疗法。
- 需增加社区患者及时获得专科诊疗的机会。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advances in the understanding of disease biology, drug development, and supportive care have led to improved outcomes in multiple myeloma. Given that these improvements have been reported in clinical trial and referral center populations, questions remain about the generalizability of this observation to patients treated in the community. Contrasting the overall survival experience of 3783 patients seen at Mayo Clinic and 57,654 patients followed in the Surveillance, Epidemiology, and End Results Program (SEER) between 2004 and 2018, we observed different mortality trends across patient populations and subgroups. Early mortality decreased and estimated 5-year overall survival increased over time in both patient populations. Excess mortality (compared to the general population) declined over time in Mayo Clinic patients and remained largely unchanged in SEER patients. Improvements over time were primarily observed in patients with favorable disease characteristics and older patients with multiple myeloma remain a vulnerable population with significant excess mortality compared to the United States general population. Patients with unfavorable disease characteristics have derived disproportionately less benefit from recent advances in the field. Future efforts need to focus on the development of safe and effective therapies for these patients and on increasing timely access to specialized care for patients in the community.
引用
- Binder M, Nandakumar B, Rajkumar SV, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2021. PMID: 34702976. doi:10.1038/s41375-021-01453-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。